EGFR and non-small cell lung carcinoma: The presence of EGFR mutations defines a specific molecular subgroup of NSCLC (~15% of Caucasian patients with adenocarcinomas) [37, 38] that respond to an EGFR TKI in over 60% of patients (Table 1).